ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2011
IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy.
Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00252538 (Genetic and Biochemical Markers of Interferon-Induced Depression.), which is not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic and Biochemical Markers of Interferon-Induced Depression.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Genetic Contributions of Inflammation to Depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Pooled it
- Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.PloS one · 2014Pooled it
- Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.BMC medicine · 2013Pooled it
- Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.Psychopharmacology · 2016Article
- Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.Pharmaceuticals (Basel, Switzerland) · 2015Article
- Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.Journal of gastroenterology · 2014Article
- Neuroimmune basis of methamphetamine toxicity.International review of neurobiology · 2014Review
- Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.Journal of psychosomatic research · 2013Article
- Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.Neuroscience · 2013Review
- Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Depression in Late-Life: a Focus on Prevention.Focus (American Psychiatric Publishing) · 2013Article
- Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.Journal of psychosomatic research · 2013Article
- Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes.World journal of gastroenterology · 2012Article
- The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-α (IFN-α) treatment for hepatitis C virus (HCV) is complicated by depression and related neurovegetative side effects. Recent genome-wide scans identified IL28B gene polymorphisms that associated with HCV clearance. Whether the IL28B polymorphism is also associated with these adverse effects of IFN-α would affect its clinical usefulness. One hundred thirty-three patients were prospectively examined using the Beck Depression Inventory-II and a Structured Clinical Interview for Diagnostic and Statistical Manual-IV (DSM-IV) during IFN-α treatment. The candidate C/T single-nucleotide polymorphism upstream from IL28B (rs1297860) was genotyped and assessed for association with individual items from the Beck Depression Inventory-II. We confirmed that the IL28B polymorphism was associated with differences in sustained viral response (F = 3.38; P < 0.05), with the T/T genotype faring worst. However, the T/T genotype was associated with less appetite (P < 0.05), energy (P < 0.05), and sleep complaints (P < 0.05) during treatment. Only 3.1% of patients with T/T developed major appetite complaints, whereas 10.1% and 8.9% of those with the C/T and C/C genotype did, respectively. Only 10.8% of patients with T/T developed major sleep complaints, whereas 16.1% and 20.7% of those with the C/T and C/C genotype did. However, IL28B genotype did not predict development of major depressive disorder (χ(2) = 0.12; P = 0.94). The allele (C) was associated with both better viral clearance and more subjective appetite, energy, and sleep complaints. This has implications for the management of patients with HCV. If genotyping is used to better target therapy, this may co-enrich the population for likelihood of also suffering from these side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.